Referencia número: HY-B0692

Cefepime

(Synonyms: BMY-28142)

18 Cited Publications

Revisión del cliente

Based on 18 publication(s) in Google Scholar

Cefepime (BMY-28142) is a broad-spectrum, blood-brain barrier-permeable cephalosporin antibiotic with hPON1 inhibitory activity, with an IC₅₀ of 21.115 mM and a K_i of 35.092 mM. Cefepime inhibits hPON1 via a non-competitive mechanism and blocks GABA_A receptors. Cefepime penetrates the outer membrane of Gram-negative bacteria, inhibits the growth of Gram-positive and Gram-negative bacteria, and does not induce the production of β-lactamase.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.86%
No. CAS: 88040-23-7
Fòrmula: C₁₉H₂₄N₆O₅S₂
Peso molecular:480.56

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Cefepime Chemical Structure

No. CAS: 88040-23-7

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (18)
Solvente y solubilidad
- In Vitro
- In Vivo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

IC₅₀ & Target

β-lactam

Ver todos los productos específicos de isoformas Antibiotic :

Cellular Effect

Cell Line	Type	Value	Description	References
HeLa	IC₅₀	1700 μM Compound: Cefepime	TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.02 uM) in OCTN2-expressing HeLa cells TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.02 uM) in OCTN2-expressing HeLa cells	[PMID: 10636865]

In Vitro

Cefepime (18 h) potently inhibits most isolates of Gram-negative aerobic bacteria. Among these pathogens, the MIC₉₀ value is ≤1 mg/L for most Enterobacteriaceae, 16 mg/L for Pseudomonas aeruginosa, and ≤0.12 mg/L for Haemophilus influenzae, Neisseria gonorrhoeae and Branhamella catarrhalis^[4].
Cefepime (18-48 h) inhibits Gram-positive bacterial isolates, with an MIC₉₀ value of ≤ 4 mg/L against staphylococci and an MIC₉₀ value of ≤ 0.25 mg/L against most streptococci, but shows limited activity against Enterococcus faecalis, Listeria monocytogenes and Bacteroides species^[4].
Cefepime exhibits stable in vitro activity across different culture media, pH values, and inoculum sizes. For most isolates, the difference between its MIC and MBC values is extremely small, but the MBC values of Pseudomonas aeruginosa and Staphylococcus aureus in human serum are higher^[4].
Cefepime (2-8×MIC; 2-24 h) exhibits concentration-dependent bactericidal activity against Enterobacter cloacae (with the strongest activity and no regrowth observed at 8×MIC), sustained bactericidal activity against Pseudomonas aeruginosa, but only limited transient activity against Methicillin (HY-121544)-resistant Staphylococcus aureus^[4].
Cefepime (1 mM) exhibits high stability against almost all tested plasmid-mediated and chromosome-mediated bacterial β-lactamases, and is only slightly hydrolyzed by the PSE-2 enzyme^[4].
Cefepime is a weak inhibitor of most bacterial β-lactamases, exhibiting only weak activity against Proteus vulgaris Ic enzyme and Pseudomonas aeruginosa Id enzyme, with an IC₅₀ value of > 400 mg/L against the key clinical β-lactamases TEM-1 and P99^[4].
Cefepime exhibited only marginal differences in MIC values among Escherichia colipermeability mutants, whereas an 8-fold difference was observed among Pseudomonas aeruginosapermeability mutants, indicating that its ability to enhance bacterial cell wall penetration is limited^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Cefepime induces bacterial stasis in a neutropenic murine thigh infection model infected with Enterobacteriaceae and Klebsiella pneumoniae, under the condition that the unbound drug concentration remains above the MIC for 0-37.7% of the dosing interval^[2].
Cefepime (250-500 mg/kg; intravenous bolus) does not increase the susceptibility to pentylenetetrazol (PTZ)-induced convulsions in normal male ICR mice^[3].
Cefepime (250-500 mg/kg; intravenous bolus) significantly increases the average seizure grade to 3.3 in the low-current electroshock-induced seizure model of normal male ICR mice, while the 250 mg/kg dose increases the average seizure grade to 2.0^[3].
Cefepime (500 mg/kg; intravenous bolus) induces convulsions in 2 out of 3 normal male ICR mice, and elicits electroencephalogram spike waves in the parietal cortex of 1 mouse following low-current electroshock stimulation^[3].
Cefepime (500 mg/kg; intravenous bolus) significantly increases the average seizure grade induced by low-current electroconvulsive shock to 4.0 in cornea-kindled male ICR mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male CD-1 mice^[4]
Dosage:

80 mg/kg
Administration:

I.p.
Result:

Significantly prolonged the half-life of cefepime and all mice survived at 18-22 mg/kg cisplatin, and when pretreatment with 26 mg/kg cisplatin significantly decreased survival with the half-life of cefepime was not significantly longer than of 18 mg/kg cisplatin.

Chemical Information

No. CAS 88040-23-7
Appearance Solid
Peso molecular 480.56
Fòrmula C₁₉H₂₄N₆O₅S₂
Color White to light yellow
SMILES

C[N+]1(CC(CS[C@]2([H])[C@@H]3NC(/C(C4=CSC(N)=N4)=N\OC)=O)=C(C([O-])=O)N2C3=O)CCCC1
Synonyms

BMY-28142
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (18)

All Microbiological Assay

Sort by:

Journal Impact Factor

J Exp Med

Antibiotic use in early life impairs MAIT cell-mediated immunity in adulthood. [Abstract]

2026 Mar 2;223(3):e20241287. PMID: 41400657
Emerg Microbes Infect

AMXT-1501 targets membrane phospholipids against Gram-positive and -negative multidrug-resistant bacteria. [Abstract]

2024 Dec;13(1):2321981. PMID: 38422452
Pharmaceutics

Stability Studies of Antipseudomonal Beta Lactam Agents for Outpatient Therapy. [Abstract]

2023 Nov 30;15(12):2705. PMID: 38140046
Virulence

Antibacterial efficacy and mechanism of the novel antimicrobial peptide lachnospirin-1 against Acinetobacter baumannii. [Abstract]

2026 Dec 31;17(1):2646808. PMID: 41838520
Molecules

Seeking Correlation Among Porin Permeabilities and Minimum Inhibitory Concentrations Through Machine Learning: A Promising Route to the Essential Molecular Descriptors. [Abstract]

2025 Mar 9;30(6):1224. PMID: 40142001
Int J Antimicrob Agents

Elucidating adaptive compensatory tigecycline resistance mechanisms of RamA, RarA and SoxS in Klebsiella pneumoniae. [Abstract]

2025 Oct;66(4):107551. PMID: 40499596
Antimicrob Agents Chemother

Individual target pharmacokinetic/pharmacodynamic attainment rates among cefepime-treated patients admitted to the ICU with hospital-acquired pneumonia with and without ECMO. [Abstract]

2025 Jun 4;69(6):e0010225. PMID: 40372025
J Antimicrob Chemother

Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study. [Abstract]

2026 Feb 2;81(3):dkag034. PMID: 41648989

Cefepime purchased from MedChemExpress. Usage Cited in: J Antimicrob Chemother. 2026 Feb 2;81(3):dkag034. [Abstract]

Activities of new β-lactam/β-lactamase inhibitors (Cefepime, et al.) against AmpC-hyperproducing E. cloacae complex and Klebsiella aerogenes were evaluated.
J Antimicrob Chemother

Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction. [Abstract]

2025 Nov 5:dkaf408. PMID: 41206063
J Glob Antimicrob Resist

Genomic characterization of carbapenem-resistant Pseudomonas aeruginosa from ICU admission screening in Hanoi, Vietnam, 2023. [Abstract]

2025 Jul 7:44:265-271. PMID: 40633763
Anim Dis

Pasteurella multocida capsular: lipopolysaccharide types D:L6 and A:L3 remain to be the main epidemic genotypes of pigs in China. [Abstract]

2021;1(1):26. PMID: 34778886
Infect Genet Evol

Polymyxin B combined with amikacin delays the resistance of Klebsiella pneumoniae to polymyxin B by modulating the expression of NlpE. [Abstract]

2025 Sep:133:105780. PMID: 40480594

Cefepime purchased from MedChemExpress. Usage Cited in: Infect Genet Evol. 2025 Sep:133:105780. [Abstract]

Antibiotic sensitivity of K. pneumoniae Kp81 and its derivatives.
Vet Microbiol

Discovery of the tigecycline resistance gene cluster tmexCD3-toprJ1 in Pasteurella multocida strains isolated from pigs in China. [Abstract]

2024 May:292:110046. PMID: 38471428

Cefepime purchased from MedChemExpress. Usage Cited in: Vet Microbiol. 2024 May:292:110046. [Abstract]

MICs for 16 antimicrobial agents against 381 strains of P. multocida from pigs.
^a AMP: ampicillin, AMX: amoxicillin, CEF: ceftiofur, CIP: ciprofloxacin, COL: colistin, CPM: Cefepime, DOX: doxycycline, ENR: enrofloxacin, ERY: erythromycin, FFC: florfenicol, GEN: gentamicin, IPM: imipenem, SPT: spectinomycin, TET: tetracycline, TGC: tigecycline, TIL: tilmicosin.
^b NA: breakpoint not available.
^c veterinary-specific breakpoints applicable to porcine P. multocida from CLSI VET01S ED7:2024; light grey shading – susceptible, dark grey shading – intermediate, black shading – resistant.
J Antibiot (Tokyo)

Impact of short chain fatty acids (SCFAs) on antimicrobial activity of new β-lactam/β-lactamase inhibitor combinations and on virulence of Escherichia coli isolates. [Abstract]

2023 Apr;76(4):225-235. PMID: 36726014

Cefepime purchased from MedChemExpress. Usage Cited in: J Antibiot (Tokyo). 2023 Apr;76(4):225-235. [Abstract]

Susceptibility patterns of E. coli isolates (n = 140) towards different β-Lactams singly and in combination with β-Lactamase inhibitors (CFP Cefoperazone, CAZ Ceftazidime, FEP Cefepime). The results showed that cephalosporins were effective against E. coli isolates at the following rates: cefoperazone (52.9%), ceftazidime (43.5%), and Cefepime (32.1%).
J Infect Chemother

Application of epithelial lining fluid drug concentrations to MICi-Based PK/PD modeling of cefepime/nacubactam in a murine model of CPE pneumonia. [Abstract]

2025 Dec 8;32(1):102889. PMID: 41371496
Res Sq

2026 Mar 9.
Patent

US20240209004A1.
bioRxiv

2024 May 10.

Solvente y solubilidad

In Vitro:

DMSO : 116.67 mg/mL (242.78 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 100 mg/mL (208.09 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0809 mL

10.4045 mL

20.8091 mL

5 mM

0.4162 mL

2.0809 mL

4.1618 mL

10 mM

0.2081 mL

1.0405 mL

2.0809 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.33 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (4.33 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.33 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (284 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Türkeş C, et al. Human serum paraoxonase-1 (hPON1): in vitro inhibition effects of moxifloxacin hydrochloride, levofloxacin hemihidrate, cefepime hydrochloride, cefotaxime sodium and ceftizoxime sodium. J Enzyme Inhib Med Chem. 2015;30(4):622-628. [Content Brief]

[2]. Pais GM, et al. Clinical Pharmacokinetics and Pharmacodynamics of Cefepime. Clin Pharmacokinet. 2022;61(7):929-953. [Content Brief]

[3]. Tanaka A, et al. Convulsive liability of cefepime and meropenem in normal and corneal kindled mice. Antimicrob Agents Chemother. 2014;58(8):4380-4383. [Content Brief]

[4]. Neu HC, et al. The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin. J Antimicrob Chemother. 1986;17(4):441-452. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	2.0809 mL	10.4045 mL	20.8091 mL	52.0226 mL
	5 mM	0.4162 mL	2.0809 mL	4.1618 mL	10.4045 mL
	10 mM	0.2081 mL	1.0405 mL	2.0809 mL	5.2023 mL
	15 mM	0.1387 mL	0.6936 mL	1.3873 mL	3.4682 mL
	20 mM	0.1040 mL	0.5202 mL	1.0405 mL	2.6011 mL
	25 mM	0.0832 mL	0.4162 mL	0.8324 mL	2.0809 mL
	30 mM	0.0694 mL	0.3468 mL	0.6936 mL	1.7341 mL
	40 mM	0.0520 mL	0.2601 mL	0.5202 mL	1.3006 mL
	50 mM	0.0416 mL	0.2081 mL	0.4162 mL	1.0405 mL
	60 mM	0.0347 mL	0.1734 mL	0.3468 mL	0.8670 mL
	80 mM	0.0260 mL	0.1301 mL	0.2601 mL	0.6503 mL
	100 mM	0.0208 mL	0.1040 mL	0.2081 mL	0.5202 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Cefepime

18 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Cefepime

Anti-Infection Compound Library

Membrane Transporter/Ion Channel Compound Library

Neuronal Signaling Compound Library

FDA-Approved Drug Library

CNS-Penetrant Compound Library

Drug Repurposing Compound Library

Antibacterial Compound Library

NMPA-Approved Drug Library

Neurotransmitter Receptor Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Anti-Alzheimer's Disease Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Rare Diseases Drug Library

GABA Receptor Compound Library

Human Metabolite Library

Heterocyclic Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Ion Channel Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Cefepime

Ver todos los productos específicos de isoformas Antibiotic

Actividad biológica

Chemical Information

Publications (18)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Cefepime Related Classifications

HY-B0692 Related Classifications